MariSubklewe

@MSubklewe

Interests: #AML,#Lymphoma, #Immunotherapy, #BiTE,#CART,#MRD

LMU-University Hospital Munich genzentrum.uni-muenchen.de/research-group… Joined August 2020

372 Following 835 Followers 130 Posts

Latest posts 5

MariSubklewe @MSubklewe May 23, 2025

150+ women from all career stages came together at #FAME2025 – Females in Academic Medicine – at @LMU_Muenchen's Medical Faculty.
A vibrant, strong space for exchange, inspiration & solidarity.
Thanks to @WiebkeArlt, @AnnaFrebel & all who made it possible.
#ConnectForChange

MariSubklewe @MSubklewe May 12, 2025

New in @BloodJournal: STING activation boosts CD33xCD3 mediated T cell cytotoxicity in #AML by creating an IFN-g- driven feedback loop. Happy to co-lead this with @VeitHornung, and kudos to first authors Andreas Linder & Daniel Nixdorf ! doi.org/10.1182/blood.…

ashpublications.org STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia Key PointsThe efficacy of AMG 330 against AML cells is greatly enhanced by combining it with a STING agonist.IFN-γ plays a key role in AMG 330–mediated cyt

MariSubklewe @MSubklewe Apr 20, 2024

Going beyond Cancer with T cell engagers: First-in-human report on a CD19 TCE for safe & successful treatment in systemic sclerosis. EJC in press. @OncologyAdvance

MariSubklewe @MSubklewe Sep 8, 2023

Check out our @EHA_Hematology @TheEBMT consensus guidelines for a new distinct toxicity category of immune effector cell therapy (CAR-T, BsAb): ICAHT!

See link above for the accompanying commentary !

Also featured in the @BloodJournal podcast 👇
ashpublications.org/blood/pages/bl…

MariSubklewe @MSubklewe Jun 11, 2023

Kudos to the #EHA #EBMT team on putting together #ICAHT consensus guidelines now published in @BloodJournal. Grateful for this incredible European collaboration and a special shoutout to @KRejeski